ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Lung Cancer
Neoplasm Metastasis
Non-Small-Cell Lung Carcinoma
Adenocarcinoma

Colon Cancer trials near New Haven, CT, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: CAPEOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

New Haven, Connecticut, United States and 250 other locations

(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer...

Enrolling
Colon Cancer
Metastatic Colon Cancer
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

New Haven, Connecticut, United States and 13 other locations

dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...

Active, not recruiting
Any Solid Tumor
Glioma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Commack, New York, United States and 32 other locations

is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

New Haven, Connecticut, United States and 16 other locations

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...

Enrolling
Any Solid Tumor
Colon Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

New Haven, Connecticut, United States and 83 other locations

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

Phase 2, Phase 3

NRG Oncology
NRG Oncology

New Haven, Connecticut, United States and 878 other locations

known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Squamous Cell Cancer of Head and Neck (SCCHN)
Drug: TAK-186

Phase 1, Phase 2

Takeda
Takeda

New Haven, Connecticut, United States and 19 other locations

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemipl...

Active, not recruiting
Breast Cancer
Colon Cancer
Biological: E-602
Biological: Cemiplimab

Phase 1, Phase 2

Palleon Pharmaceuticals

New Haven, Connecticut, United States and 12 other locations

evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

Phase 1, Phase 2

Mirati Therapeutics
Mirati Therapeutics

New Haven, Connecticut, United States and 219 other locations

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...

Active, not recruiting
Metastatic Colorectal Cancer
Advanced Colorectal Cancer
Drug: MRTX849
Biological: Cetuximab

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Shirley, New York, United States and 282 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems